Simulations Plus, Inc. (SLP)
| Market Cap | 270.35M -60.9% |
| Revenue (ttm) | 80.54M +2.5% |
| Net Income | -62.79M |
| EPS | -3.12 |
| Shares Out | 20.21M |
| PE Ratio | n/a |
| Forward PE | 32.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 286,991 |
| Open | 13.57 |
| Previous Close | 13.57 |
| Day's Range | 13.27 - 13.73 |
| 52-Week Range | 11.09 - 34.01 |
| Beta | 1.28 |
| Analysts | Buy |
| Price Target | 24.00 (+79.37%) |
| Earnings Date | Apr 9, 2026 |
About SLP
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for SLP stock is "Buy." The 12-month stock price target is $24.0, which is an increase of 79.37% from the latest price.
News
Simulations Plus, Nvidia collaborate to scale AI-assisted modeling workflows
Simulations Plus (SLP) announced the launch of a technical collaboration with NVIDIA (NVDA) focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive model...
Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus enters funded research collaboration with Lonza, FDA
Simulations Plus (SLP) announced a funded research collaboration with Lonza Group (LZAGY) and the U.S. Food and Drug Administration to develop and validate a mechanistic, predictive framework for asse...
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus announces completion of 2026 Spring School
Simulations Plus (SLP) announced the completion of its 2026 Spring School, a global training initiative designed to expand access to model-informed drug development and strengthen the scientific found...
Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus price target lowered to $16 from $19 at TD Cowen
TD Cowen lowered the firm’s price target on Simulations Plus (SLP) to $16 from $19 and keeps a Hold rating on the shares. The firm said they reported solid Q2…
Simulations Plus Earnings Call Transcript: Q2 2026
Revenue grew 8% to $24.3M in Q2, with strong software and services performance, improved gross margins, and robust cash reserves. AI integration and pharma collaborations are driving future growth, though management remains cautious due to macro risks.
Simulations Plus reports Q2 adjusted EPS 35c, consensus 31c
Reports Q2 revenue $24.3M, consensus $21.66M. “We delivered solid second quarter results, with revenue increasing by 8%,” said Shawn O’Connor, CEO of Simulations Plus (SLP). “Software growth was drive...
Simulations Plus cuts FY26 adjusted EPS view to 75c-85c from $1.03-$1.10
Consensus $1.02. Backs FY26 revenue view $79M-$82M, consensus $80.42M.
Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Options Volatility and Implied Earnings Moves Today, April 09, 2026
Today, several major companies are expected to report earnings: Simply Good Foods (SMPL), Neogen (NEOG), BlackBerry (BB), Simulations Plus (SLP), WD-40 Company (WDFC), Beam Global (BEEM), AmpliTech Gr...
Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances bio...
Simulations Plus announces collaboration programs for AI-enabled modeling
Simulations Plus (SLP) announced strategic collaboration programs with three large pharmaceutical companies to advance artificial intelligence workflows across the drug development lifecycle. These pr...
Simulations Plus Announces Strategic Collaboration Programs for AI-Enabled Modeling
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus Transcript: TD Cowen 46th Annual Health Care Conference
The platform is expanding from point solutions to an integrated AI-enabled ecosystem, with a focus on cross-selling, value-based pricing, and deeper pharma engagement. FY 2026 growth is guided at 0%-4%, with stronger performance expected in the second half and significant AI-driven revenue upside anticipated in FY 2027.
Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus Transcript: AGM 2026
The meeting covered board elections, auditor ratification, an equity plan amendment, and executive compensation vote frequency. All proposals passed with strong support, and no shareholder questions were submitted during the Q&A.
Simulations Plus announces extensions of FDA and NIEHS research collaborations
Simulations Plus (SLP) announced the extension of two separate research collaborations with the U.S. FDA and the National Institute of Environmental Health Sciences, or NIEHS. The extended projects su...
Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus to Participate in Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances bio...
Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus Transcript: Investor Day 2026
A unified, AI-enabled ecosystem is being developed to support the full drug development lifecycle, leveraging cloud, validated science, and integrated services. Fiscal 2026 guidance is reaffirmed, with new revenue streams and cross-selling expected to drive long-term growth and margin expansion.
Simulations Plus Earnings Call Transcript: Q1 2026
Revenue declined 3% to $18.4M, with strong services growth offsetting a 17% software drop. Gross margin improved to 59%, and guidance for FY26 remains unchanged, anticipating 0–4% revenue growth and a software mix of 57–62%.
Simulations Plus reports Q1 adjusted EPS 13c, consensus 20c
Reports Q1 revenue $18.4M, consensus $18.06M. “We met our first quarter revenue guidance and delivered strong performance in our services segment, driven primarily by significant growth in commerciali...